Home > Boards > US OTC > Biotechs >

Delcath Systems Inc. (DCTH)

Add DCTH Price Alert      Hide Sticky   Hide Intro
Moderator: Filterthenoise
Search This Board: 
Last Post: 3/27/2020 8:02:13 AM - Followers: 518 - Board type: Free - Posts Today: 0

Web Site: Delcath Systems, Inc.
Stock and Financial Info: OTC Marketplace
About Delcath Systems (OTCQB:DCTH)
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Their proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)-is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company's principal focus is on the treatment of primary and metastatic liver cancers. In the United States, the Melphalan/HDS system is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). The Melphalan/HDS system has not been approved for sale in the United States. In Europe, their proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). In April 2012, they obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT system. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has commenced a global phase 2 clinical trial in Europe to investigate Melphalan/HDS system for primary liver cancer and is initiating plans to evaluate intrahepatic cholangiocarcinoma.
Delcath Systems was formed in 1988 as a Pharmaceutical and Medical Device company focused on oncology. The company is registered in Delaware with offices in New York, New York and Manufacturing, Distribution, Research and Development facilities located in Queensbury, New York. The company currently has 10 patents in their US Intellectual Property portfolio according to the US Patent Office.
Subsidiaries of Delcath Systems include Delcath Holdings Limited (Ireland), Delcath Systems Limited (Ireland), Delcath Systems B.V. (Netherlands), Delcath Systems Gmbh (Germany) and Delcath Systems UK (United Kingdom).
Delcath Systems Securities
Delcath Systems securities originally came on the market on June 16, 2000 with an IPO offering of 1.2m shares priced at $6.00 per share. Securities were listed on both the NASDAQ and Boston Stock Exchange. The stock moved from the NASDAQ to the OTCQB on September 15, 2017 after the company Voluntarily Delisted it from NASDAQ and requested an Accelerated listing in the OTC marketplace.

Stock Split History
The stock has been (reverse) split a total of 4 times. Twice while on the NASDAQ and twice since moving to the OTCQB.
The 1st split came on April 9, 2014 at a ratio of 1:16
The 2nd split came on July 21, 2016 at a ratio of 1:16
The 3rd split came on November 6, 2017 at a ratio of 1:350
The 4th split came on May 2, 2018 at a ratio of 1:500

Delcath Share Information
Common Shares Authorized: 1,000,000,000
Preferred Shares Authorized: 
Common Shares Outstanding*: 17,464,807 (a/o 5/01/2019)
Preferred Shares Outstanding**: (a/o 4/02/2019) 

Fully Diluted Common Shares as of November 5, 2018 ***

* From OTC Markets on 05/01/2019 / ** From SEC Filing 04/02/1019 / *** From SEC Filing on 11/07/2018
Delcath Systems Clinical Trials
Declcath Systems currently has two clinical trials underway. The first is the FOCUS Trial and the second the ALIGN Trial.
The FOCUS Trial is designed to evaluate patients who have melanoma that has spread from the eye to the liver. All patients in the study will be treated with Melphalan/HDS for up to 6 treatments. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment. The FOCUS Trial has an estimated completion date of April 2020. For more info click here  
The ALIGN Trial will evaluate two groups of patients who have intrahepatic cholangiocarcinoma. Each group will receive induction treatment with Cisplatin and Gemcitabine per SOC for 4 treatment cycles. Following induction treatment patients will be randomize (1:1), to 2 arms of treatment. One group (50%) will rreceive high dose chemotherapy delivered specifically to the liver, while the other group (50%) will continue treatment with Cisplatin and Gemcitabine. Patient in each group will get repeating cycles of treatment until the cancer advances. All patients will be followed until death. This study will compare the overall survival (OS) in patients with intrahepatic cholangiocarcinoma. The ALIGN Trial has an estimated completion date of January 2023. For more info click here
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
DCTH News: Current Report Filing (8-k) 02/19/2020 04:01:05 PM
DCTH News: Amended Statement of Ownership (sc 13g/a) 02/13/2020 04:01:15 PM
DCTH News: Securities Registration Statement (s-1/a) 02/07/2020 05:26:36 PM
DCTH News: Statement of Ownership (sc 13g) 02/05/2020 02:18:07 PM
DCTH News: Prospectus Filed Pursuant to Rule 424(a) (424a) 02/03/2020 06:13:28 AM
#49731   Probably the only way to know the big SAMNOTSAMUEL 03/27/20 08:02:13 AM
#49730   SNS, currently stuck in Nigeria with power outages DesertEagle 03/27/20 05:36:01 AM
#49729   Down tremendously. No momentum. Saw other stocks Muenster Madness 03/26/20 06:52:06 PM
#49728   Being ever so lazy, is there any monumentally SAMNOTSAMUEL 03/26/20 12:29:48 PM
#49727   10K is out. Only $10 million cash at SAMNOTSAMUEL 03/26/20 12:26:08 PM
#49726   MM, have been watching you for a while DesertEagle 03/26/20 05:26:11 AM
#49725   #DCTH 10-K out, iHub not listing filings? DesertEagle 03/26/20 03:45:09 AM
#49724   I sold all my shares to play the Muenster Madness 03/25/20 08:26:56 PM
#49723   SNS, not sure if you looked at $REGN DesertEagle 03/18/20 05:34:14 AM
#49722   Would like to know what those guys/gals are DesertEagle 03/17/20 08:51:43 AM
#49721   It looks like possible infusion of money could SAMNOTSAMUEL 03/17/20 08:27:47 AM
#49720   Any reason the new filing was not posted DesertEagle 03/17/20 06:46:34 AM
#49719   31,360,000,000 @ $188,166,000,000 DesertEagle 03/17/20 06:29:19 AM
#49718   Want to see volume... let DCTH do a DesertEagle 03/11/20 06:01:52 AM
#49717   I mostly agree with that, but without volume SAMNOTSAMUEL 03/10/20 10:58:54 AM
#49716   Survival skills she has, but retail will not DesertEagle 03/10/20 10:40:44 AM
#49715   It is a mighty loser for practically all SAMNOTSAMUEL 03/10/20 10:19:47 AM
#49714   NASDAQ any Day, Week, Month or Year? DesertEagle 03/10/20 02:57:33 AM
#49713   Man. What a time to reinvest. Oil looks Muenster Madness 03/09/20 08:14:04 PM
#49712   One thing is entirely mathematics. There must be SAMNOTSAMUEL 03/05/20 04:58:56 PM
#49711   The story is so bizarre it will likely Filterthenoise 03/05/20 02:53:51 PM
#49710   The new wrinkle is the big boys have SAMNOTSAMUEL 03/05/20 08:00:39 AM
#49709   This sure look to be accumulated very well Filterthenoise 03/04/20 06:53:18 PM
#49708   Wow, just looked as Jennifer got way over SAMNOTSAMUEL 02/29/20 08:50:08 AM
#49707   Not in anymore was in the past completely Johnstonj27 02/29/20 03:07:07 AM
#49706   If that’s truly the case then I’m the Muenster Madness 02/28/20 03:39:38 PM
#49705   Straight from OTC trade data. DesertEagle 02/28/20 01:48:37 PM
#49704   I think you are a bit low, but SAMNOTSAMUEL 02/28/20 12:43:05 PM
#49703   Only 167 shares traded in the last 10 DesertEagle 02/28/20 06:27:13 AM
#49702   Should be hitting the Nasdaq any time now Muenster Madness 02/25/20 02:03:47 PM
#49701   I would assume she is not a factor. SAMNOTSAMUEL 02/21/20 12:37:23 PM
#49700   Elizabeth Czerepak = more losses? DesertEagle 02/21/20 09:44:25 AM
#49699   It is not much of a defense but SAMNOTSAMUEL 02/20/20 01:49:39 PM
#49697   I have many old investor friends. The reason DesertEagle 02/20/20 08:50:56 AM
#49696   I have many new investor friends. They Muenster Madness 02/12/20 08:10:31 PM
#49695   I consider the greatest risk would be getting SAMNOTSAMUEL 02/12/20 01:06:38 PM
#49694   Considering their has been no correspondence with the DesertEagle 02/12/20 10:26:44 AM
#49693   Should get NASDAQ decision anytime withing 2 weeks. Filterthenoise 02/10/20 10:41:29 PM
#49692   You are spot on. That would be best SAMNOTSAMUEL 02/10/20 05:01:23 PM
#49691   Ask at $16. Board seems dead. Wiser Muenster Madness 02/10/20 04:57:20 PM
#49690   700:1 is bank robbery lister 02/05/20 12:45:24 PM
#49689   autsch, perhaps next year the next one lister 02/05/20 12:29:16 PM
#49688   There was a 700 to 1 reverse split, SAMNOTSAMUEL 02/04/20 05:55:37 PM
#49687   what was the ratio? lister 02/04/20 02:19:21 PM
#49686   As long as many days have tiny volume SAMNOTSAMUEL 01/31/20 05:30:25 PM
#49685   I read Nasdaq approvals take approx. 4-6 weeks. Filterthenoise 01/31/20 03:19:15 PM
#49684   Maybe news after hours. Something positive would be nice Muenster Madness 01/31/20 02:46:19 PM
#49683   2000 shares for sale now at $12.00. 70,000 SAMNOTSAMUEL 01/30/20 11:20:02 AM
#49682   The shares are 69,000 outstanding as of end SAMNOTSAMUEL 01/23/20 11:16:01 AM
#49681   The debacle continues, I see... IB says 39.5k kaufmaga 01/23/20 10:52:55 AM